Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares traded down 6.8% during mid-day trading on Thursday. The stock traded as low as $23.23 and last traded at $22.9560. Approximately 9,660 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 92,531 shares. The stock had previously closed at $24.62.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on NBTX. Guggenheim initiated coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.
Check Out Our Latest Analysis on Nanobiotix
Nanobiotix Price Performance
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.
Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.
The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors.
Featured Stories
- Five stocks we like better than Nanobiotix
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
- Why Light Is the New AI Bottleneck—And 3 Photonics Stocks to Play It
- Nasdaq’s Business Is Outrunning Its Stock
- Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
